Vascular sympathetic neurotransmission and its serotonergic regulation are modified by chronic fluoxetine treatment
Given the interconnection between depressive and cardiovascular disorders, we investigated whether antidepressant treatment (fluoxetine) modifies the serotonergic influence on rat vascular noradrenergic outflow. Twelve-week-old male Wistar rats received fluoxetine treatment (10 mg/kg/day; p.o.) for...
Main Authors: | , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2021-09-01
|
Series: | Journal of Pharmacological Sciences |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S1347861321000505 |
_version_ | 1818453491865092096 |
---|---|
author | José Ángel García-Pedraza Cristina López Juan Francisco Fernández-González María Luisa Martín Asunción Morán Mónica García-Domingo |
author_facet | José Ángel García-Pedraza Cristina López Juan Francisco Fernández-González María Luisa Martín Asunción Morán Mónica García-Domingo |
author_sort | José Ángel García-Pedraza |
collection | DOAJ |
description | Given the interconnection between depressive and cardiovascular disorders, we investigated whether antidepressant treatment (fluoxetine) modifies the serotonergic influence on rat vascular noradrenergic outflow. Twelve-week-old male Wistar rats received fluoxetine treatment (10 mg/kg/day; p.o.) for 14 days; then, they were pithed and prepared for sympathetic stimulation. Vasopressor responses were obtained by electrical stimulation of the sympathetic outflow (0.1, 0.5, 1, and 5 Hz) or i.v. noradrenaline (NA; 0.01, 0.05, 0.1, and 0.5 μg/kg). In fluoxetine-treated group, the electrical-induced vasoconstrictions were lower compared to non-treated rats. Intravenous infusion of 5-HT (10 μg/kg/min) inhibited the sympathetically-induced vasoconstrictions. Only 5-CT, 8-OH-DPAT and L-694,247 (5-HT1/7, 5-HT1A and 5-HT1D agonists, respectively) mimicked 5-HT-induced inhibition, while α-methyl-5-HT (5-HT2 agonist) increased the vasopressor responses. The inhibitory effect of 5-HT was: a) no modified by SB269970 (5-HT7 antagonist); b) abolished by WAY-100,635 (5-HT1A antagonist) plus LY310762 (5-HT1D antagonist); and c) potentiated by ritanserin (5-HT2A receptor antagonist). The vasoconstrictions induced by exogenous NA were not modified by 5-CT but were increased by α-methyl-5-HT. Our results suggest that fluoxetine treatment decreases NA release at vascular level and changes 5-HT modulation on rat vascular noradrenergic neurotransmission, inducing sympatho-inhibition via prejunctional 5-HT1A/1D receptors, and sympatho-potentiation via pre and/or postjunctional 5-HT2A receptors. |
first_indexed | 2024-12-14T21:39:50Z |
format | Article |
id | doaj.art-85090b45d91a455c88f3ccb1b99c62c3 |
institution | Directory Open Access Journal |
issn | 1347-8613 |
language | English |
last_indexed | 2024-12-14T21:39:50Z |
publishDate | 2021-09-01 |
publisher | Elsevier |
record_format | Article |
series | Journal of Pharmacological Sciences |
spelling | doaj.art-85090b45d91a455c88f3ccb1b99c62c32022-12-21T22:46:29ZengElsevierJournal of Pharmacological Sciences1347-86132021-09-0114714857Vascular sympathetic neurotransmission and its serotonergic regulation are modified by chronic fluoxetine treatmentJosé Ángel García-Pedraza0Cristina López1Juan Francisco Fernández-González2María Luisa Martín3Asunción Morán4Mónica García-Domingo5Laboratory of Pharmacology, Department of Physiology and Pharmacology, Faculty of Pharmacy, University of Salamanca, 37007, Salamanca, Spain; Research Institute of Salamanca (IBSAL), Paseo San Vicente 58-182, 37007, Salamanca, SpainLaboratory of Pharmacology, Department of Physiology and Pharmacology, Faculty of Pharmacy, University of Salamanca, 37007, Salamanca, SpainLaboratory of Pharmacology, Department of Physiology and Pharmacology, Faculty of Pharmacy, University of Salamanca, 37007, Salamanca, Spain; Research Institute of Salamanca (IBSAL), Paseo San Vicente 58-182, 37007, Salamanca, SpainLaboratory of Pharmacology, Department of Physiology and Pharmacology, Faculty of Pharmacy, University of Salamanca, 37007, Salamanca, Spain; Research Institute of Salamanca (IBSAL), Paseo San Vicente 58-182, 37007, Salamanca, SpainLaboratory of Pharmacology, Department of Physiology and Pharmacology, Faculty of Pharmacy, University of Salamanca, 37007, Salamanca, Spain; Research Institute of Salamanca (IBSAL), Paseo San Vicente 58-182, 37007, Salamanca, SpainLaboratory of Pharmacology, Department of Physiology and Pharmacology, Faculty of Pharmacy, University of Salamanca, 37007, Salamanca, Spain; Research Institute of Salamanca (IBSAL), Paseo San Vicente 58-182, 37007, Salamanca, Spain; Corresponding author. Laboratory of Pharmacology, Department of Physiology and Pharmacology, Faculty of Pharmacy, University of Salamanca, 37007, Salamanca, Spain. Fax: +34 923 29 45 15.Given the interconnection between depressive and cardiovascular disorders, we investigated whether antidepressant treatment (fluoxetine) modifies the serotonergic influence on rat vascular noradrenergic outflow. Twelve-week-old male Wistar rats received fluoxetine treatment (10 mg/kg/day; p.o.) for 14 days; then, they were pithed and prepared for sympathetic stimulation. Vasopressor responses were obtained by electrical stimulation of the sympathetic outflow (0.1, 0.5, 1, and 5 Hz) or i.v. noradrenaline (NA; 0.01, 0.05, 0.1, and 0.5 μg/kg). In fluoxetine-treated group, the electrical-induced vasoconstrictions were lower compared to non-treated rats. Intravenous infusion of 5-HT (10 μg/kg/min) inhibited the sympathetically-induced vasoconstrictions. Only 5-CT, 8-OH-DPAT and L-694,247 (5-HT1/7, 5-HT1A and 5-HT1D agonists, respectively) mimicked 5-HT-induced inhibition, while α-methyl-5-HT (5-HT2 agonist) increased the vasopressor responses. The inhibitory effect of 5-HT was: a) no modified by SB269970 (5-HT7 antagonist); b) abolished by WAY-100,635 (5-HT1A antagonist) plus LY310762 (5-HT1D antagonist); and c) potentiated by ritanserin (5-HT2A receptor antagonist). The vasoconstrictions induced by exogenous NA were not modified by 5-CT but were increased by α-methyl-5-HT. Our results suggest that fluoxetine treatment decreases NA release at vascular level and changes 5-HT modulation on rat vascular noradrenergic neurotransmission, inducing sympatho-inhibition via prejunctional 5-HT1A/1D receptors, and sympatho-potentiation via pre and/or postjunctional 5-HT2A receptors.http://www.sciencedirect.com/science/article/pii/S13478613210005055-HTFluoxetineNoradrenalineSympathetic neurotransmissionVascular tone |
spellingShingle | José Ángel García-Pedraza Cristina López Juan Francisco Fernández-González María Luisa Martín Asunción Morán Mónica García-Domingo Vascular sympathetic neurotransmission and its serotonergic regulation are modified by chronic fluoxetine treatment Journal of Pharmacological Sciences 5-HT Fluoxetine Noradrenaline Sympathetic neurotransmission Vascular tone |
title | Vascular sympathetic neurotransmission and its serotonergic regulation are modified by chronic fluoxetine treatment |
title_full | Vascular sympathetic neurotransmission and its serotonergic regulation are modified by chronic fluoxetine treatment |
title_fullStr | Vascular sympathetic neurotransmission and its serotonergic regulation are modified by chronic fluoxetine treatment |
title_full_unstemmed | Vascular sympathetic neurotransmission and its serotonergic regulation are modified by chronic fluoxetine treatment |
title_short | Vascular sympathetic neurotransmission and its serotonergic regulation are modified by chronic fluoxetine treatment |
title_sort | vascular sympathetic neurotransmission and its serotonergic regulation are modified by chronic fluoxetine treatment |
topic | 5-HT Fluoxetine Noradrenaline Sympathetic neurotransmission Vascular tone |
url | http://www.sciencedirect.com/science/article/pii/S1347861321000505 |
work_keys_str_mv | AT joseangelgarciapedraza vascularsympatheticneurotransmissionanditsserotonergicregulationaremodifiedbychronicfluoxetinetreatment AT cristinalopez vascularsympatheticneurotransmissionanditsserotonergicregulationaremodifiedbychronicfluoxetinetreatment AT juanfranciscofernandezgonzalez vascularsympatheticneurotransmissionanditsserotonergicregulationaremodifiedbychronicfluoxetinetreatment AT marialuisamartin vascularsympatheticneurotransmissionanditsserotonergicregulationaremodifiedbychronicfluoxetinetreatment AT asuncionmoran vascularsympatheticneurotransmissionanditsserotonergicregulationaremodifiedbychronicfluoxetinetreatment AT monicagarciadomingo vascularsympatheticneurotransmissionanditsserotonergicregulationaremodifiedbychronicfluoxetinetreatment |